Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.0K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

501
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
501
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

280
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
280
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

511
The pathophysiology of pneumonia involves the following steps:
511
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

905
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
905

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis.

Respiratory medicine and research·2026
Same author

Behavioural changes in exposure patterns after genetic counselling among asymptomatic first-degree relatives of patients with pulmonary fibrosis and carriers of a telomere-related gene variant.

ERJ open research·2026
Same author

Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis.

The Journal of experimental medicine·2025
Same author

Nintedanib Combined With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis: A Long-Term Retrospective Multicentre Study (Combi-PF).

Archivos de bronconeumologia·2025
Same author

Splenic stiffness does not predict esophageal varices in children with portal hypertension.

Journal of pediatric gastroenterology and nutrition·2025
Same author

Impact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis.

Respirology (Carlton, Vic.)·2025

Related Experiment Video

Updated: Sep 6, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

276

[Idiopathic pulmonary fibrosis].

Nathan Hennion1, Jean-Luc Desseyn1, Frédéric Gottrand1

  • 1Univ. Lille, Inserm, CHU Lille, U1286 Infinite, F-59000 Lille, France.

Medecine Sciences : M/S
|June 29, 2022
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease causing scarring. Current treatments only slow IPF progression, highlighting the need for better therapeutic strategies.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

822
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

2.6K

Related Experiment Videos

Last Updated: Sep 6, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

276
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

822
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

2.6K

Area of Science:

  • Pulmonology
  • Pathology
  • Pharmacology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a fatal, chronic lung disease characterized by progressive scarring of the alveolar epithelium.
  • This scarring involves excessive accumulation of extracellular matrix (ECM) driven by fibroblasts and myofibroblasts in fibroblastic foci.
  • Existing therapies offer limited efficacy, merely slowing disease progression.

Purpose of the Study:

  • To review the underlying mechanisms driving IPF progression.
  • To summarize current therapeutic approaches for IPF.
  • To discuss various study models used in IPF research.

Main Methods:

  • Literature review of scientific articles and clinical trial data.
  • Analysis ofPathomechanisms including epithelial injury, fibroblast activation, and ECM deposition.
  • Synthesis of information on approved drugs and emerging therapeutic strategies.
  • Evaluation of preclinical and clinical models for IPF investigation.

Main Results:

  • IPF pathogenesis involves complex interactions between epithelial cells, fibroblasts, and the extracellular matrix.
  • Current treatments, such as pirfenidone and nintedanib, can slow disease decline but do not halt or reverse fibrosis.
  • Various experimental models, including cell cultures and animal models, are crucial for understanding IPF and testing new therapies.

Conclusions:

  • Understanding IPF mechanisms is key to developing effective treatments.
  • There is an unmet need for therapies that can halt or reverse lung fibrosis in IPF patients.
  • Continued research utilizing diverse study models is essential for advancing IPF therapeutics.